Samamtha Hudson, MD
Endocrinology, Diabetes & Metabolism · Midlothian, VANPI 1922205475
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $322,839 of the $372,453 with a category attached, or 86.7%. Lilly USA, LLC accounts for 81.6% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $89,193, 4.3 times the $20,882 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 608 payments — averaging $612.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$304K
- Bayer$32K
- Sanofi-aventis U.S. LLC$27K
- Cequr Corporation$4K
- Medtronic$3K
- Tandem Diabetes Care, Inc.$1K
- plus $752 from 7 others
What the payments were for
- Consulting fees$1,0500%
- Speaking & faculty fees$322,83987%
- Travel & lodging$41,15411%
- Food & beverage$7,3912%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 460 | $303,774 |
| Bayer | 29 | $32,408 |
| Sanofi-aventis U.S. LLC | 38 | $27,247 |
| Cequr Corporation | 2 | $3,658 |
| Medtronic(2 entities) | 31 | $3,482 |
| Tandem Diabetes Care, Inc. | 4 | $1,132 |
| Novo Nordisk | 37 | $307 |
| Sequel Med Tech, LLC | 1 | $150 |
| Amgen | 2 | $142 |
| Ascendis Pharma Endocrinology Inc | 1 | $96 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Amarin Pharma, Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$263,180
- Kerendia$32,302
- SOLIQUA 100/33$13,758
- TOUJEO$13,004
- CeQur Simplicity$3,658
- Minimed 670G System$1,291
- t-slim insulin pump$1,050
- TWIIST$150
- TZIELD$125
- EVENITY$122
- MINIMED 780G$107
- InPen$103
How this compares
$372,453 in reported general payments places this provider in the 95th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 243 | $362,066 |
| OzempicSemaglutide | 131 | $188,663 |
| JardianceEmpagliflozin | 51 | $83,081 |
| TrulicityDulaglutide | 65 | $79,638 |
| FarxigaDapagliflozin Propanediol | 29 | $38,312 |
| KerendiaFinerenone | 30 | $29,390 |
| JanuviaSitagliptin Phosphate | 30 | $27,045 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $20,107 |
| TradjentaLinagliptin | 13 | $19,997 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $18,119 |
| RybelsusSemaglutide | 14 | $12,995 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $12,940 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 71 | $8,878 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $7,994 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 58 | $7,333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $303,774 | $441,704308 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $307 | $206,904160 claims |
| BayerKerendia | $32,408 | $29,39030 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $12 | $5,252351 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Midlothian
- Ben PhillipsMidlothian$99K
- Meredith BergerMidlothian$32K
- Christina WagnerMidlothian$8K
- Matthew LaroeMidlothian$7K
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Elias SirajNorfolk$316K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.